iSpecimen Inc.
ISPCdata completeness 88%6 fiscal years on fileData notes: no data for concept 'pretaxIncome'
iSpecimen Inc. earns about -182% on equity, but has diluted owners by 7% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $11.1M1 | $10.4M2 | $9.93M2 | $9.29M3 | $1.93M3 |
| Net income | −$8.96M4 | −$10.2M5 | −$11.1M6 | −$12.5M7 | −$10.5M7 |
| Operating cash flow | −$10.7M8 | −$5.82M9 | −$5.81M10 | −$8.26M11 | −$4.24M11 |
| Capital expenditure | $2,55012 | $215,50413 | $19,47814 | $31,54615 | $45415 |
| Free cash flow (derived) | −$10.7M8 | −$6.03M9 | −$5.83M10 | −$8.3M11 | −$4.24M11 |
| Total debt | $3.42M16 | — | — | — | — |
| Cash & equivalents | $27.7M17 | $15.3M18 | $2.34M19 | $1.88M20 | $6.88M20 |
| Diluted shares | 4.3M | 8.8M | 452,067 | 710,852 | 4.6M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $6.71 of net worth that earned you −$22.79 and generated −$9.21 of cash last year.
It earned an average -182% on equity over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is up 7% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has held roughly steady.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K/A · period ending 2021-12-31 · accession 0001558370-23-005151 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0001558370-24-003129 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-038607 (Revenues)
- 10-K/A · period ending 2021-12-31 · accession 0001558370-23-005151 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0001558370-24-003129 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001213900-25-031639 (NetIncomeLoss)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-038607 (NetIncomeLoss)
- 10-K/A · period ending 2021-12-31 · accession 0001558370-23-005151 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001558370-24-003129 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001213900-25-031639 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-038607 (NetCashProvidedByUsedInOperatingActivities)
- 10-K/A · period ending 2021-12-31 · accession 0001558370-23-005151 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-12-31 · accession 0001558370-24-003129 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0001213900-25-031639 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-038607 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0001558370-22-004077 (LongTermDebt)
- 10-K/A · period ending 2021-12-31 · accession 0001558370-23-005151 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0001558370-24-003129 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0001213900-25-031639 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-038607 (CashAndCashEquivalentsAtCarryingValue)